Jacob Ukleja

Jacob Ukleja

Auto-generated profile, based on publicly available information

Jacob Ukleja

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
NKNezihi Murat Karabacak
Nezihi Murat Karabacak
YZYu Zheng
Yu Zheng
TDTaronish D. Dubash
Taronish D. Dubash
RBRisa Burr
Risa Burr
DMDouglas S. Micalizzi
Douglas S. Micalizzi
SMShyamala Maheswaran
Shyamala Maheswaran
Cancer therapy often results in heterogeneous responses in different metastatic lesions in the same patient. Inter- and intratumor heterogeneity in signaling within various tumor compartments and its impact on therapy are not well characterized due to the limited sensitivity of single-cell proteomic approaches. To overcome this barrier, we applied single-cell mass cytometry with a customized 26-antibody panel to PTEN-deleted orthotopic prostate cancer xenograft models to measure the evolution of kinase activities in different tumor compartments during metastasis or drug treatment. Compared with primary tumors and circulating tumor cells (CTC), bone metastases, but not lung and liver metastases, exhibited elevated PI3K/mTOR signaling and overexpressed receptor tyrosine kinases (RTK) including c-MET protein. Suppression of c-MET impaired tumor growth in the bone. Intratumoral heterogeneity within tumor compartments also arose from highly proliferative EpCAM-high epithelial cells with increased PI3K and mTOR kinase activities coexisting with poorly proliferating EpCAM-low mesenchymal populations with reduced kinase activities; these findings were recapitulated in epithelial and mesenchymal CTC populations in patients with metastatic prostate and breast cancer. Increased kinase activity in EpCAM-high cells rendered them more sensitive to PI3K/mTOR inhibition, and drug-resistant EpCAM-low populations with reduced kinase activity emerged over time. Taken together, single-cell proteomics indicate that microenvironment- and cell state–dependent activation of kinase networks create heterogeneity and differential drug sensitivity among and within tumor populations across different sites, defining a new paradigm of drug responses to kinase inhibitors. Significance: Single-cell mass cytometry analyses provide insights into the differences in kinase activities across tumor compartments and cell states, which contribute to heterogeneous responses to targeted therapies.

1 February 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
PSPhilip J. Saylor
Philip J. Saylor
KOKeisuke Otani
Keisuke Otani
RBRene Balza
Rene Balza
JUJacob Ukleja
Jacob Ukleja
HPHaley Pleskow
Haley Pleskow
David T. MiyamotoDavid T. Miyamoto
David T. Miyamoto
PURPOSE: Radium-223 improves overall survival (OS) and reduces skeletal events in patients with bone metastatic castration-resistant prostate cancer (CRPC), but relevant biomarkers are lacking. We evaluated automated bone scan index (aBSI) and circulating tumor cell (CTC) analyses as potential biomarkers of prognosis and activity. PATIENTS AND METHODS: Patients with bone metastatic CRPC were enrolled on a prospective single-arm study of standard radium-223. 99mTc-MDP bone scan images at baseline, 2 months, and 6 months were quantitated using aBSI. CTCs at baseline, 1 month, and 2 months were enumerated and assessed for RNA expression of prostate cancer–specific genes using microfluidic enrichment followed by droplet digital polymerase chain reaction. RESULTS: The median OS was 21.3 months in 22 patients. Lower baseline aBSI and minimal change in aBSI (<+0.7) from baseline to 2 months were each associated with better OS ( P = .00341 and P = .0139, respectively). The higher baseline CTC count of ≥5 CTC/7.5 mL was associated with worse OS (median, 10.1 v 32.9 months; P = .00568). CTCs declined at 2 months in four of 15 patients with detectable baseline CTCs. Among individual genes in CTCs, baseline expression of the splice variant AR-V7 was significantly associated with worse OS (hazard ratio, 5.20 [95% CI, 1.657 to 16.31]; P = .00195). Baseline detectable AR-V7, higher aBSI, and CTC count ≥5 CTC/7.5 mL continued to have a significant independent negative impact on OS after controlling for prostate-specific antigen or alkaline phosphatase. CONCLUSION: Quantitative bone scan assessment with aBSI and CTC analyses are prognostic markers in patients treated with radium-223. AR-V7 expression in CTCs is a particularly promising prognostic biomarker and warrants validation in larger cohorts.

24 November 2025
Verified
Other
Open access
PDF file
NKNezihi Murat Karabacak
Nezihi Murat Karabacak
YZYu Zheng
Yu Zheng
TDTaronish D. Dubash
Taronish D. Dubash
RBRisa Burr
Risa Burr
DMDouglas S. Micalizzi
Douglas S. Micalizzi
SMShyamala Maheswaran
Shyamala Maheswaran
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition

24 November 2025
Verified
Other
Open access
PDF file
NKNezihi Murat Karabacak
Nezihi Murat Karabacak
YZYu Zheng
Yu Zheng
TDTaronish D. Dubash
Taronish D. Dubash
RBRisa Burr
Risa Burr
DMDouglas S. Micalizzi
Douglas S. Micalizzi
SMShyamala Maheswaran
Shyamala Maheswaran
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition

24 November 2025
Verified
Other
Open access
PDF file
NKNezihi Murat Karabacak
Nezihi Murat Karabacak
YZYu Zheng
Yu Zheng
TDTaronish D. Dubash
Taronish D. Dubash
RBRisa Burr
Risa Burr
DMDouglas S. Micalizzi
Douglas S. Micalizzi
SMShyamala Maheswaran
Shyamala Maheswaran
Supplementary Figure from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition